ORLANDO — At 48 weeks, MCO-010, an optogenetic therapy, demonstrated gains in visual acuity in Stargardt disease, according to a study presented at the American Academy of Ophthalmology meeting.
Kenneth C. Fan, MD, MBA, of Retina Consultants of Texas, told Healio that the treatment of Stargardt disease is a well-known unmet need in ophthalmology.
“We know that the incidence of Stargardt disease is about one in 5,000 to 10,000 people,” he said. “Stargardt disease has no approved therapy, and we know that oftentimes patients start losing vision at an early age, even as early as adolescence, and